Last 648.80
Change Today -6.00 / -0.92%
Volume 25.2K
CFBI On Other Exchanges
Symbol
Exchange
Tel Aviv
NYSE Amex
As of 10:24 AM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

can fite biopharma ltd (CFBI) Snapshot

Open
$654.80
Previous Close
$654.80
Day High
$654.20
Day Low
$645.00
52 Week High
12/23/13 - $1,670
52 Week Low
06/25/14 - $600.20
Market Cap
117.7M
Average Volume 10 Days
91.8K
EPS TTM
$-2.77
Shares Outstanding
18.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAN FITE BIOPHARMA LTD (CFBI)

can fite biopharma ltd (CFBI) Related Bloomberg News

View More Bloomberg News

can fite biopharma ltd (CFBI) Related Businessweek News

No Related Businessweek News Found

can fite biopharma ltd (CFBI) Details

Can-Fite BioPharma, Ltd., a clinical-stage biotechnology company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis, as well as completed Phase II study for the treatment of rheumatoid arthritis; completed Phase III study for the treatment of dry eye; completed Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of liver cancer; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company is headquartered in Petah-Tikva, Israel.

9 Employees
Last Reported Date: 04/24/14

can fite biopharma ltd (CFBI) Top Compensated Officers

Scientific Founder, Chief Executive Officer a...
Total Annual Compensation: 1.1M
Chief Operating & Financial Officer and Princ...
Total Annual Compensation: 782.0K
Vice President of Business Development
Total Annual Compensation: 736.0K
Compensation as of Fiscal Year 2013.

can fite biopharma ltd (CFBI) Key Developments

Can-Fite BioPharma Ltd. Reports Unaudited Consolidated Financial Results for the Six Months Ended June 30, 2014

Can-Fite BioPharma Ltd. reported unaudited consolidated financial results for the six months ended June 30, 2014. For the six months, operating loss was ILS 14,061,000 against ILS 14,254,000 for the same period of last year. Loss was ILS 12,291,000 against ILS 14,287,000 for the same period of last year. Loss attributable to equity holders of the company was ILS 12,014,000 against ILS 13,125,000 for the same period of last year. The decrease in net loss for the first half of 2014, was attributable to an increase in finance income, net. Net loss per share attributable to equity holders of the company was ILS 0.71 compared to ILS 1.11 per share a year ago. Financial income, net for the six months ended June 30, 2014 aggregated ILS 1.71 million compared to financial expenses, net of ILS 0.03 million for the same period in 2013. The increase in financial income, net in the first half of 2014 was mainly due to a decrease in the fair value of the company's warrants. Research and development expenses for the six months ended June 30, 2014 were ILS 8.64 million compared with ILS 7.66 million for the same period in 2013. Research and development expenses for the first half of 2014 comprised primarily of expenses associated with the initiation of a planned Phase II study for CF102 as well as expenses for pre-clinical studies of CF102.

Can-Fite Biopharma Ltd. Announces New Data That Shows High Efficacy for CF101 in Rheumatoid Arthritis and Psoriasis Patients

Can-Fite BioPharma Ltd. announced new data from a retrospective analysis of its autoimmune disease advanced trials that shows high efficacy of its orally bioavailable drug CF101. The retrospective study, conducted by a third party statistician group, analyzed the correlation between response to CF101 and patients' body mass index (BMI) in the Phase II/III Psoriasis interim results as well as the recently completed Phase II Rheumatoid Arthritis trial. The data shows a significant increase in the response to CF101 in patients with a BMI of over 25 in both studies. These findings corroborate the efficacy seen with other FDA approved drugs such as Cyclosporine A which was more effective in patients with high BMI. The company believes these findings will enable it to optimize the design of its forthcoming Phase III studies. Can-Fite's Phase II/III Psoriasis trial is ongoing with data expected to be released in the first quarter of 2015. The Psoriasis therapeutic market was worth $3.6 billion in 2010 and is forecast to grow to $6.7 billion by 2018, according to Global Data. The market is dominated by biological drugs that are primarily administered via intravenous injection (IV) and have potential side effects.

Can-Fite Biopharma Ltd. Gets Approval from Israeli Ministry of Health for the Use of CF102

Can-Fite BioPharma Ltd. announced that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFBI:IT 648.80 -6.00

CFBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFBI.
View Industry Companies
 

Industry Analysis

CFBI

Industry Average

Valuation CFBI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAN FITE BIOPHARMA LTD, please visit www.canfite.co.il. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.